• Double-digit revenue growth and positive adjusted operating cash flow
• Strengthening commercial profitability, driving growth in Precision Medicine segment
• Expanded global operations in Telix Manufacturing Solutions to deliver patient outcomes

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) today announces its financial results for the year ended December 31, 2025. The company reported revenue of US$803.8 million, up by 56% and achieving upsized full year guidance. Adjusted EBITDA was US$39.5 million, reflecting increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure, and research and development (R&D). The Precision Medicine segment saw revenue up by 22% year-over-year, driven by continued increase in Illuccix® volumes and the successful launch of Gozellix® in the U.S. Telix also expanded its global operations in Telix Manufacturing Solutions, including the acquisition of RLS, to deliver patient outcomes. The company invested US$157.1 million in R&D for late-stage therapeutics and precision medicine pipeline assets, and achieved several milestones in its Therapeutics pipeline, including completing target enrollment for Part 1 of the ProstACT® Global Phase 3 study in metastatic castration resistant prostate cancer and receiving regulatory approvals to commence several new clinical trials. Telix provided FY 2026 Group Revenue guidance of US$950 million to US$970 million and pipeline R&D expenditure guidance of US$200 million to US$240 million.

Telix provides FY 2026 Group Revenue guidance of US$950 million to US$970 million, reflecting revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS. Telix also provides pipeline R&D expenditure guidance of US$200 million to US$240 million.

Telix is focused on delivery of near-term priorities to further strengthen the foundations for long-term revenue and earnings growth, including accelerating its best-in-class therapeutic pipeline, expanding the Precision Medicine growth opportunity through label expansion studies and new product launches, and continuing to expand its global production and manufacturing footprint.